001     310005
005     20260223120901.0
024 7 _ |a 10.1016/j.clnu.2026.106597
|2 doi
024 7 _ |a pmid:41719624
|2 pmid
024 7 _ |a 0261-5614
|2 ISSN
024 7 _ |a 1532-1983
|2 ISSN
037 _ _ |a DKFZ-2026-00418
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wang, Youqing
|0 P:(DE-He78)5a18ac1d8e95a59d44c072d0a7dba4b7
|b 0
|e First author
|u dkfz
245 _ _ |a Impact of vitamin D supplementation on all-cause mortality: Randomized trials revisited.
260 _ _ |a Amsterdam [u.a.]
|c 2026
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771842406_3895552
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a EA:M320#LA:M320#
520 _ _ |a Vitamin D insufficiency and deficiency are common worldwide and linked to adverse health outcomes, including higher all-cause mortality. Two large randomized controlled trials (VITAL and D-Health), conducted in mostly vitamin D-sufficient populations, found no mortality benefits of vitamin D supplementation. This study aims to estimate the expected effects of vitamin D supplementation in target populations with vitamin D insufficiency or deficiency..We emulated the VITAL and D-Health trials using data from the UK Biobank cohort to estimate expected effects of the observed increases in serum 25-hydroxyvitamin-D (25(OH)D) concentrations by 30 nmol/L and 38 nmol/L. In alternative analyses, study populations meeting the trial inclusion criteria (n = 237,502 and 185,809) were either weighted to yield distributions of 25(OH)D as observed in the trials, or restricted to people with vitamin D insufficiency or deficiency. Expected effects on all-cause mortality over the mean trial follow up times (5.3 and 5.7 years) were estimated using Cox models.Emulated trials with study populations weighted to the 25(OH)D distributions of the original trials yielded null results similar to those reported (hazard ratios [HR] 0.97 [95 % CI: 0.92-1.02] and 1.02 [95%CI: 0.97-1.07]). In contrast, major mortality reduction was expected in emulated trials that were restricted to people with vitamin insufficiency (HR 0.85 [95%CI: 0.79-0.91] and 0.81 [95%CI: 0.76-0.86]) or deficiency (HR 0.79 [95%CI: 0.72-0.87] and 0.75 [95%CI: 0.69-0.81])..Null effects of vitamin D supplementation were to be expected in trials conducted in vitamin D sufficient populations. Emulated trials suggest a potential for major mortality reduction in vitamin D insufficient and deficient populations..
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a All-cause mortality
|2 Other
650 _ 7 |a Dose-response
|2 Other
650 _ 7 |a Emulation
|2 Other
650 _ 7 |a Randomized controlled trials
|2 Other
650 _ 7 |a Vitamin D
|2 Other
700 1 _ |a Sha, Sha
|0 P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780
|b 1
|u dkfz
700 1 _ |a Gwenzi, Tafirenyika
|0 P:(DE-He78)35a941418cdcc6c595b7a8a19e355599
|b 2
|u dkfz
700 1 _ |a Schöttker, Ben
|0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
|b 3
|u dkfz
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.clnu.2026.106597
|g Vol. 58, p. 106597 -
|0 PERI:(DE-600)2009052-3
|p 106597
|t Clinical nutrition
|v 58
|y 2026
|x 0261-5614
909 C O |o oai:inrepo02.dkfz.de:310005
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)5a18ac1d8e95a59d44c072d0a7dba4b7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)1d6f6305a65e2f7de2c7fbffbae83780
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)35a941418cdcc6c595b7a8a19e355599
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2026
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-28
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN NUTR : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CLIN NUTR : 2022
|d 2024-12-28
920 2 _ |0 I:(DE-He78)M320-20160331
|k M320
|l Koordinierungsstelle der Cancer Prevention GS
|x 0
920 1 _ |0 I:(DE-He78)M320-20160331
|k M320
|l Koordinierungsstelle der Cancer Prevention GS
|x 0
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie der Krebsfrüherkennung
|x 1
920 0 _ |0 I:(DE-He78)M320-20160331
|k M320
|l Koordinierungsstelle der Cancer Prevention GS
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)M320-20160331
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21